Residency · Residency · Family Medicine

Urinary Tract Infections: From Uncomplicated Cystitis to Pyelonephritis

Overview

Urinary tract infections are among the most common bacterial infections managed in primary care, with approximately 50 to 60% of women experiencing at least one UTI in their lifetime. Optimal management requires appropriate diagnostic criteria, antibiotic selection guided by local resistance patterns, and careful avoidance of overtreatment, particularly of asymptomatic bacteriuria in populations where treatment causes more harm than benefit.

Classification

Uncomplicated cystitis refers to a lower urinary tract infection in a non-pregnant, premenopausal woman without urologic abnormalities. Complicated UTI encompasses infections in men, pregnant women, patients with structural or functional urinary tract abnormalities, immunocompromised individuals, those with indwelling catheters, and renal transplant recipients. Pyelonephritis is an upper urinary tract infection involving the renal parenchyma. Recurrent UTI is defined as two or more infections in 6 months or three or more in 12 months. Asymptomatic bacteriuria refers to the presence of significant bacteria in the urine without any accompanying symptoms.

Microbiology

Escherichia coli is the causative organism in 75 to 95% of uncomplicated UTIs. Staphylococcus saprophyticus is the second most common pathogen in young women, accounting for 5 to 15% of cases. Klebsiella pneumoniae, Proteus mirabilis, and Enterococcus species are more commonly implicated in complicated UTIs. Pseudomonas aeruginosa is associated with catheter-associated and healthcare-associated infections. ESBL-producing organisms are a rising concern, with risk factors including recent antibiotic use, hospitalization, and travel to endemic areas.

Diagnosis

Uncomplicated Cystitis

Uncomplicated cystitis in women can be diagnosed clinically based on classic symptoms of dysuria, frequency, urgency, and suprapubic pain. When a woman presents with dysuria and frequency without vaginal symptoms, the probability of UTI approaches 90%. On urinalysis, pyuria (10 or more WBC per high-power field or positive leukocyte esterase) is highly sensitive, while nitrites are specific but less sensitive because only Enterobacterales produce them. Urine culture is not required for uncomplicated cystitis and should be reserved for situations of diagnostic uncertainty, recurrent infections, or treatment failure. Phone-based diagnosis and empiric treatment is appropriate for women with classic symptoms and a history of prior UTI.

When to Obtain Urine Culture

Urine culture should be obtained in complicated UTI (including infections in men, pregnant women, and those with anatomic abnormalities), pyelonephritis, recurrent UTI, treatment failure or early relapse, recent antibiotic use where resistance is a concern, and healthcare-associated infections.

Pyelonephritis Diagnosis

Pyelonephritis presents with flank pain, costovertebral angle tenderness, fever of 38 degrees Celsius or above, and nausea or vomiting, with or without lower urinary tract symptoms. Urinalysis and urine culture should always be obtained. Blood cultures are indicated for hospitalized patients, immunocompromised individuals, or when the source of infection is uncertain. CT of the abdomen and pelvis with contrast is appropriate when abscess, obstruction, or complicated pyelonephritis is suspected.

Treatment

Uncomplicated Cystitis - First-Line

Nitrofurantoin monohydrate/macrocrystals at 100 mg twice daily for 5 days is a first-line option. It should be avoided when eGFR falls below 30 because inadequate urinary concentration limits its efficacy, and it does not achieve systemic levels, making it ineffective for pyelonephritis. Trimethoprim-sulfamethoxazole at 160/800 mg twice daily for 3 days is another first-line agent, provided local E. coli resistance does not exceed 20%, and it should be avoided in the third trimester of pregnancy. Fosfomycin as a 3-gram single dose offers convenience but is slightly less effective than a 5-day course of nitrofurantoin and can be expensive with limited availability.

Uncomplicated Cystitis - Second-Line

Beta-lactams such as amoxicillin-clavulanate at 500/125 mg three times daily for 5 to 7 days or cefpodoxime at 100 mg twice daily for 3 days are less effective than first-line agents and are reserved for situations involving resistance or allergy. Fluoroquinolones such as ciprofloxacin at 250 mg twice daily or levofloxacin at 250 mg daily for 3 days should be avoided for uncomplicated cystitis because of FDA black box warnings regarding tendon rupture, peripheral neuropathy, and aortic dissection risk. These agents should be reserved for more serious infections.

Pyelonephritis - Outpatient

Outpatient management is appropriate for patients who are non-toxic, tolerating oral intake, have reliable follow-up, and have no complicating factors. Ciprofloxacin at 500 mg twice daily for 5 to 7 days is an option when local resistance is below 10%. TMP-SMX at 160/800 mg twice daily for 14 days may be used if susceptibility is confirmed. Ceftriaxone 1 gram IM or IV as a single dose followed by oral step-down therapy with TMP-SMX or a fluoroquinolone for 10 to 14 days is another approach. An initial dose of ceftriaxone is recommended before starting oral therapy when non-fluoroquinolone regimens are chosen.

Pyelonephritis - Inpatient

Hospitalization is indicated for patients with sepsis, severe nausea and vomiting, inability to tolerate oral medications, pregnancy, suspected obstruction, or immunocompromise. Inpatient regimens include ceftriaxone 1 to 2 grams IV daily, piperacillin-tazobactam 3.375 grams IV every 6 hours, or ciprofloxacin 400 mg IV every 12 hours. Transition to oral therapy is appropriate once the patient has been clinically improving and afebrile for 24 to 48 hours.

Special Populations

UTI in Men

UTIs in men are always considered complicated, and urine culture should be obtained. The differential includes prostatitis, urethritis from sexually transmitted infections, and structural abnormalities. Treatment consists of TMP-SMX or a fluoroquinolone for 7 to 14 days, with fluoroquinolones preferred for their superior prostatic penetration. Urologic referral is warranted for a first UTI in a young man or for recurrent infections.

UTI in Pregnancy

All pregnant women should be screened for asymptomatic bacteriuria at the first prenatal visit, typically at 12 to 16 weeks. Treatment of ASB in pregnancy is critical because it reduces the risk of pyelonephritis from 20 to 40% down to 1 to 4%. Safe antibiotics include nitrofurantoin (avoided at term), cephalexin, amoxicillin-clavulanate, and fosfomycin. Fluoroquinolones, TMP-SMX (which acts as a folate antagonist in the first trimester and poses a kernicterus risk in the third), and tetracyclines should all be avoided. Duration of treatment is 4 to 7 days for cystitis and 10 to 14 days for pyelonephritis. A test-of-cure urine culture should be obtained 1 to 2 weeks after completing treatment.

UTI in Elderly

Nonspecific symptoms such as confusion and falls should not be attributed to UTI without concurrent urinary symptoms. Asymptomatic bacteriuria is extremely common in the elderly, affecting up to 50% of nursing home residents, and should not be treated. Cloudy or foul-smelling urine alone is not an indication for antibiotics. Treatment is appropriate only when urinary symptoms are present alongside a positive culture.

Catheter-Associated UTI (CAUTI)

Catheter-associated UTI should be diagnosed only when symptoms are present (fever, rigors, flank pain, new confusion) and the culture shows 1000 or more colony-forming units per milliliter. The catheter should be changed or removed before obtaining the culture to avoid biofilm contamination. Asymptomatic catheter-associated bacteriuria should not be treated.

Asymptomatic Bacteriuria (ASB)

When to Screen and Treat

Asymptomatic bacteriuria should be screened for and treated in pregnancy and before urologic procedures where mucosal bleeding is expected. It should not be screened for or treated in the elderly, diabetics, patients with indwelling catheters, those with spinal cord injuries, or premenopausal non-pregnant women.

Common Overtreatment Scenario

A nursing home resident with altered mental status and a positive urinalysis does not necessarily have a UTI. Bacteriuria and pyuria are ubiquitous in catheterized patients and common in the elderly, and reflexive treatment should be avoided. Treating asymptomatic bacteriuria in elderly patients increases adverse drug events, Clostridioides difficile risk, and antimicrobial resistance without providing clinical benefit.

Recurrent UTI Prevention

Non-Antibiotic Strategies

Vaginal estrogen, available as cream, ring, or tablet, is the most effective non-antibiotic preventive strategy in postmenopausal women, reducing UTI risk by 36 to 75%. Despite this strong evidence, it remains dramatically underutilized. Cranberry products offer modest benefit with a number needed to treat of approximately 25, with capsules preferred over juice, though they are not considered first-line. D-mannose at 2 grams daily has limited but promising evidence suggesting it may prevent E. coli adhesion to the urinary epithelium. The REDUCTION trial demonstrated that increasing fluid intake by 1.5 liters of additional water daily reduced UTI frequency by 50%. Post-coital voiding is routinely recommended though the supporting evidence is limited.

Antibiotic Prophylaxis

Continuous low-dose prophylaxis with nitrofurantoin at 50 to 100 mg nightly or TMP-SMX at 40/200 mg nightly for 6 to 12 months is effective. Post-coital prophylaxis using a single dose of nitrofurantoin or TMP-SMX after intercourse is appropriate when UTIs are coitus-related. Self-start therapy, in which the patient initiates treatment with a pre-prescribed antibiotic at symptom onset, is an evidence-based strategy that empowers patients and reduces unnecessary clinic visits.

<image>A diagnostic and treatment algorithm for UTI beginning with symptom assessment, differentiating uncomplicated cystitis (empiric treatment without culture) from complicated UTI and pyelonephritis (culture-guided treatment). Show first-line and second-line antibiotic choices with doses and durations for each category. Include a separate pathway for asymptomatic bacteriuria with clear treat/do-not-treat indications.</image>

<image>An antibiotic selection guide infographic for UTI showing the recommended agents organized by tier (first-line, second-line, avoid), with key properties for each: spectrum of coverage, resistance rates, important side effects, pregnancy safety, and renal dosing considerations. Highlight fluoroquinolone black box warnings and the rationale for avoiding them in uncomplicated cystitis.</image>

<image>A clinical scenarios grid showing common UTI management pitfalls: (1) elderly patient with confusion and positive UA but no urinary symptoms = do NOT treat ASB, (2) pregnant woman with positive urine culture and no symptoms = DO treat ASB, (3) catheterized patient with cloudy urine but no systemic symptoms = do NOT treat, (4) young woman with classic dysuria/frequency = treat empirically without culture. Use check and X marks for correct/incorrect actions.</image>

Clinical Pearls

Uncomplicated cystitis in women with classic symptoms can be diagnosed clinically, and urine culture is not required and adds cost without changing management. Nitrofurantoin and TMP-SMX are preferred over fluoroquinolones for uncomplicated cystitis because fluoroquinolones carry FDA black box warnings and should be reserved for more serious infections. Asymptomatic bacteriuria should only be treated in pregnancy and before urologic procedures; treating ASB in elderly patients causes harm. Vaginal estrogen is the most effective non-antibiotic intervention for recurrent UTI prevention in postmenopausal women, yet it is dramatically underutilized. Altered mental status in an elderly patient with a positive urinalysis is not necessarily a UTI, and reflexive antibiotic prescribing should be avoided. Local antibiogram data should guide empiric antibiotic selection, and if local E. coli TMP-SMX resistance exceeds 20%, an alternative first-line agent should be used. Fosfomycin is a convenient single-dose option but is slightly less effective than a 5-day course of nitrofurantoin. For recurrent UTIs, patient self-start therapy is an evidence-based strategy that reduces unnecessary clinic visits while empowering patients to manage their condition.

References

• Gupta K et al. IDSA/ESCMID Guidelines for Uncomplicated Cystitis and Pyelonephritis. Clin Infect Dis. 2011
• Nicolle LE et al. IDSA Guidelines for Asymptomatic Bacteriuria. Clin Infect Dis. 2019
• Hooton TM et al. Recurrent UTI in Women. JAMA. 2024
• ACOG Committee Opinion: Urinary Tract Infections in Pregnant Women. 2020
• Hooton TM et al. Effect of Increased Daily Water Intake on Recurrent UTI (REDUCTION). JAMA Intern Med. 2018
• FDA Drug Safety Communication: Fluoroquinolone Safety. 2018

Read this lecture as Markdown